Glucosio S.A.L.F.

Glucosio S.A.L.F. is a sterile intravenous solution containing glucose monohydrate as the active ingredient. It is supplied as a solution for injection, intended for parenteral administration in clinical settings. The product conforms to EU pharmaceutical standards and is classified as an excipient used to provide an immediate source of carbohydrate energy. The formulation is supplied in sterile containers suitable for pharmacy use.

Glucosio S.A.L.F. is used as an intravenous carbohydrate source in a variety of clinical situations where rapid energy supplementation is required.

- To provide caloric support during short‑term fasting or pre‑operative preparation. - As a diluent or carrier for compatible parenteral medications. - To correct hypoglycemia when oral intake is not feasible. - In fluid resuscitation protocols where glucose is needed alongside electrolytes. - For maintenance of blood glucose levels during total parenteral nutrition (TPN) admixtures.

When administered intravenously, Glucosio S.A.L.F. may be associated with a range of observed effects, most of which are related to the glucose load.

Common: - Transient hyperglycemia that resolves with metabolic clearance. - Mild venous irritation at the infusion site. - Temporary increase in serum osmolality. - Nausea or mild abdominal discomfort in susceptible individuals.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Electrolyte imbalance, particularly hypokalemia. - Allergic or anaphylactoid reaction to formulation excipients. - Fluid overload in patients with compromised cardiac function.

Healthcare professionals should observe specific precautions when selecting Glucosio S.A.L.F. for intravenous therapy to minimize risks.

- Verify patient’s baseline blood glucose and adjust infusion rate accordingly. - Avoid use in patients with known hypersensitivity to glucose solutions or excipients. - Monitor electrolytes, especially potassium, during prolonged administration. - Assess cardiac and renal function before large‑volume infusions. - Use aseptic technique to prevent contamination of the sterile solution. - Store the product according to manufacturer guidelines to maintain stability.

Glucose monohydrate solutions can interact with other intravenous agents, influencing their efficacy or safety.

Avoid: - Co‑administration with high‑dose insulin without appropriate glucose monitoring. - Simultaneous infusion with potassium chloride solutions that may precipitate.

Use with caution: - Concurrent use of diuretics that can exacerbate electrolyte shifts. - Administration alongside catecholamines, as glucose may affect hemodynamic response. - Mixing with certain antibiotics that are unstable in high‑glucose environments.